Correlation between changes in the gastrointestinal microbiota with the onset and complications of Parkinson's disease: the role of inflammatory cytokines in the bidirectional gut-brain axis
DOI:
https://doi.org/10.33448/rsd-v10i2.12788Keywords:
Microbiota; Parkinson's Disease; Neurodegeneration; Inflammation; Cytokines.Abstract
Humans developed a symbiotic relationship with their gut microbiota, a complex microbial community made up of bacteria, archaea, protists and viruses, including bacteriophages. The enteric nervous system (SNE) is a gateway to bidirectional communication between the brain and the intestine, mainly through the vagus nerve (VN). Therefore, environmental exposure plays a fundamental role in both the composition and functionality of the intestinal microbiome and can contribute to susceptibility to neurodegenerative disorders, such as Parkinson's disease (PD). This is a systematic review of the literature using the data bases PUBMED, Scielo and MEDLINE, using the descriptors present in the Health Sciences Descriptors (DeCS): Parkinson's disease, cytokines, microbiota and gastrointestinal tract. It can be mentioned that the neuropathological characteristic of PD is the generalized appearance of alpha-synuclein (α-Syn) aggregates in the central and peripheral nervous systems, including the SNE. Many studies suggest that intestinal toxins can induce the formation of α-Syn aggregates in the SNE, which can then be transmitted to the CNS via the VN. PD is strongly associated with aging and its negative effects on homeostatic mechanisms that protect against inflammation, oxidative stress and protein malfunction. Thus, this study intends to carry out, based on analyzes of inflammatory cytokines and intestinal microbiota, how dysbiosis can contribute to the onset or complications of PD, promoting a correlation between clinical and laboratory manifestations and prognosis, as well as describing the main mechanisms causal factors that are still poorly understood.
References
Camacho-Soto, A., Gross, A., Nielsen, S. S., Dey, N., & Racette, B. A. (2018). Inflammatory bowel disease and risk of Parkinson's disease in Medicare beneficiaries. Parkinsonism & related disorders, 50, 23-28.
Darby, T. M., Owens, J. A., Saeedi, B. J., Luo, L., Matthews, J. D., Robinson, B. S., ... & Jones, R. M. (2019). Lactococcus Lactis Subsp. cremoris is an efficacious beneficial bacterium that limits tissue injury in the intestine. Iscience, 12, 356-367.
Gazerani, P. (2019). Probiotics for Parkinson’s disease. International journal of molecular sciences, 20(17), 4121.
Gogokhia, L., Buhrke, K., Bell, R., Hoffman, B., Brown, D. G., Hanke-Gogokhia, C., ... & Round, J. L. (2019). Expansion of bacteriophages is linked to aggravated intestinal inflammation and colitis. Cell host & microbe, 25(2), 285-299.
Gründemann, J., Schlaudraff, F., Haeckel, O., & Liss, B. (2008). Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic acids research, 36(7), e38.
Hasegawa, S., Goto, S., Tsuji, H., Okuno, T., Asahara, T., Nomoto, K., ... & Hirayama, M. (2015). Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease. PloS one, 10(11), e0142164.
Kim, D. S., Choi, H. I., Wang, Y., Luo, Y., Hoffer, B. J., & Greig, N. H. (2017). A new treatment strategy for Parkinson's disease through the gut–brain axis: the glucagon-like peptide-1 receptor pathway. Cell transplantation, 26(9), 1560-1571.
Lee, H. S., Lobbestael, E., Vermeire, S., Sabino, J., & Cleynen, I. (2021). Inflammatory bowel disease and Parkinson’s disease: common pathophysiological links. Gut, 70(2), 408-417.
Miraglia, F., & Colla, E. (2019). Microbiome, Parkinson’s disease and molecular mimicry. Cells, 8(3), 222.
Neurath, M. F. (2014). Cytokines in inflammatory bowel disease. Nature Reviews Immunology, 14(5), 329-342.
Pereira, A. S., Shitsuka, D. M., Parreira, F. J., & Shitsuka, R. (2018). Metodologia da pesquisa científica.
Radhakrishnan, D. M., & Goyal, V. (2018). Parkinson's disease: A review. Neurology India, 66(7), 26.
Santos, S. F., De Oliveira, H. L., Yamada, E. S., Neves, B. C., & Pereira Jr, A. (2019). The gut and Parkinson's Disease—a bidirectional pathway. Frontiers in neurology, 10, 574.
Souza, C. F. M., Almeida, H. C. P., Sousa, J. B., Costa, P. H., Silveira, Y. S. S., & Bezerra, J. C. L. (2011). A doença de parkinson e o processo de envelhecimento motor. Revista Neurociências, 19(4), 718-723.
Stefanis, L. (2012). α-Synuclein in Parkinson's disease. Cold Spring Harbor perspectives in medicine, 2(2), a009399.
Strandwitz, P., Kim, K. H., Terekhova, D., Liu, J. K., Sharma, A., Levering, J., ... & Lewis, K. (2019). GABA-modulating bacteria of the human gut microbiota. Nature microbiology, 4(3), 396-403.
Tysnes OB, Storstein A. Epidemiology of Parkinson's disease (2017). J Neural Transm. 124 (8), 901-905.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Pablo Cleber Sousa Lopes Sales; Almir Vieira de Sousa Neto; Lahuan Araujo Costa; Mikhail de Morais Veras da Fonseca; Gabriela de Souza Mendonça; Ligia Viana de Araújo; Vitória Stefanny Cunha Araújo; Ana Maria Santos Cardoso; Paulo Victor de Sousa Jordão; Brenda Dias Araujo; Charles Ponte de Sousa Filho; Louise Ribeiro Teixeira; José Guilherme de Oliveira Rodrigues Ferreira ; Rafaela Costa Pacheco; André Pessoa Silva Bastos; Brenda Ellen Meneses Cardoso; Larruama Soares Figueiredo de Araújo; Bianca Sampaio Lima; Vivian Saeger Pires; Luan Kelves Miranda de Souza

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.